Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan

Author： Hoskins Janelle M   Rosner Gary L   Ratain Mark J   McLeod Howard L   Innocenti Federico  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.10, Iss.7, 2009-07, pp. : 1139-1146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

High-dose lisinopril feasible in high-risk patients with HF

By  

Inpharma, Vol. 1, Iss. 1271, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated with Cetuximab: A Meta-Analysis

By Wang Long  

Drugs in R&D, Vol. 11, Iss. 4, 2011-12 ,pp. : 317-326

Adis International

Access to resources Recommend Favorite

Cost––effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer

By Obradovic Marko   Mrhar Ales   Kos Mitja  

Pharmacogenomics, Vol. 9, Iss. 5, 2008-05 ,pp. : 539-549

Future Medicine

Access to resources Recommend Favorite

High-Dose Chemotherapy in Breast Cancer

By Lake Diana E.   Hudis Clifford A.  

Drugs, Vol. 64, Iss. 17, 2004-01 ,pp. : 1851-1860

Adis International

Access to resources Recommend Favorite

Linezolid in patients with neutropenia and cancer

By  

Inpharma, Vol. 1, Iss. 1393, 2003-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite